{"id":4599,"date":"2024-07-24T13:00:43","date_gmt":"2024-07-24T03:00:43","guid":{"rendered":"\/eu-uk\/?p=4599"},"modified":"2024-07-29T13:13:04","modified_gmt":"2024-07-29T03:13:04","slug":"proactive-interview-with-paul-anderson-2","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/07\/24\/proactive-interview-with-paul-anderson-2\/","title":{"rendered":"Proactive | Interview with Paul Anderson"},"content":{"rendered":"<p>Following the announcement that Orthocell is accelerating its global market expansion of Striate+\u2122 and Remplir\u2122, Managing Director Paul Anderson spoke with Jonathan Jackson at Proactive about the Company&#8217;s seven regulatory applications in progress or planned, targeting approval in significant markets.<\/p>\n<p>Paul spoke of the positive feedback from clinicians on Orthocell\u2019s innovative regenerative medicine products and plans to capture a meaningful share of the global market as part of the Company\u2019s growth strategy.<\/p>\n<p><em>\u201cOrthocell has always focused on providing solutions for clinicians. When you combine those that are available to us, from both our dental bone product and our nerve product, we&#8217;re talking about $3 billion a year in addressable markets. We\u2019re very confident, given the outstanding uptake that we&#8217;ve seen for both Striate+ and Remplir, that we can drive towards a 20% market share of that market. And we think that we can do that with our partners, in conjunction with the excellent product and education that we provide to surgeons internationally.\u201d<\/em><\/p>\n<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/IluPc22GsNE?si=zafLrSE5uoZuzecU&amp;controls=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following the announcement that Orthocell is accelerating its global market expansion of Striate+\u2122 and Remplir\u2122, Managing Director Paul Anderson spoke with Jonathan Jackson at Proactive about the Company&#8217;s seven regulatory applications in progress or planned, targeting approval in significant markets. Paul spoke of the positive feedback from clinicians on Orthocell\u2019s innovative regenerative medicine products and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":4602,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-4599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4599"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4599\/revisions"}],"predecessor-version":[{"id":4600,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4599\/revisions\/4600"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4602"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4599"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}